Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | CPN1 | P15169 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL9344153 | 0.94 | TDP1 (0.33) | TDP1MMP2MMP9SLC6A2SLC6A4 | |
| SCHEMBL23829716 | 0.84 | — | — | |
| SCHEMBL6438537 | 0.84 | ALDH1A1 (0.40) | MMP2MMP9ALDH1A1 | |
| SCHEMBL9875012 | 0.84 | ALDH1A1 (0.40) | MMP2MMP9ALDH1A1 | |
| SCHEMBL8957450 | 0.80 | — | — | |
| SCHEMBL8259490 | 0.80 | MMP2 (0.38) | MMP2MMP9SLC6A4ALDH1A1 | |
| SCHEMBL9799676 | 0.78 | GABRP (0.40) | TDP1MMP2MMP9ALDH1A1GABRA5 | |
| SCHEMBL8957322 | 0.78 | CCNA2 (0.41) | MMP2MMP9ALDH1A1 | |
| SCHEMBL5151436 | 0.77 | CHRNB2 (0.38) | MMP2MMP9SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL13714711 | 0.76 | TDP1 (0.34) | TDP1SLC6A2SLC6A4HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665472-B1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LTD (IE) | 2022-07-06 | — | — | EP | disclosed |
| EP-2665472-B1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LTD (IE) | 2022-07-06 | — | — | EP | disclosed |
| US-9566342-B2 | Compounds for treatment of heart failure | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2017-02-14 | — | — | US | disclosed |
| US-9566342-B2 | Compounds for treatment of heart failure | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2017-02-14 | — | — | US | disclosed |
| US-9566342-B2 | Compounds for treatment of heart failure | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2017-02-14 | — | — | US | disclosed |
| CN-103145705-B | Beta-carboline alkaloid derivative, its preparation method and medicinal use thereof | NANTONG UNIVERSITY (CN) | 2016-04-06 | — | — | CN | disclosed |
| US-20130338118-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2013-12-19 | — | — | US | disclosed |
| EP-2665472-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | Solvotrin Innovations Limited (IE) | 2013-11-27 | — | — | EP | disclosed |
| CN-103145705-A | Beta-carboline alkaloid derivatives and their preparation method and medical use | UNIV NANTONG | 2013-06-12 | — | — | CN | disclosed |
| WO-2012076667-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | SOLVOTRIN INNOVATIONS LIMITED (IE) | 2012-06-14 | — | — | WO | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2007123818-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007016136-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006099058-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-0366004-B1 | Cyclic azaaliphatic compounds with a nitroxy group, process for their preparation and pharmaceutical compositions thereof | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-30 | — | — | EP | disclosed |
| US-5280031-A | Cyclic azaaliphatic compounds with a nitroxy function, processes for the preparation thereof and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1994-01-18 | — | — | US | disclosed |
| US-5030641-A | Treatment of angina pectoris, hypotensive agents | BOEHRINGER MANNHEIM GMBH (DE) | 1991-07-09 | — | — | US | disclosed |
| EP-0366004-A1 | Cyclic azaaliphatic compounds with a nitroxy group, process for their preparation and pharmaceutical compositions thereof | Roche Diagnostics GmbH (DE) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS3, NOS1, NOS2 | TDP1 346/4885MMP2 2167/4885MMP9 1181/4885 |
| US-20130338118-A1 | COMPOUNDS FOR TREATMENT OF HEART FAILURE | MMP9, NOS2, MMP1 | TDP1 2127/4885MMP2 13/4885MMP9 1/4885 |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NOS3, REN, NOS1 | TDP1 1551/4885MMP2 908/4885MMP9 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.